STEPHEN DAROY: Open Payments
NPI 1740905652 · BELLEVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,754 in 218 payments from 17 companies in 2025. Trend: 2023 $144 · 2024 $1,647 · 2025 $3,754
Food & beverage: $3,643Education: $111
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 29 | $681 |
| Teva Pharmaceuticals USA, Inc. | 23 | $608 |
| ABBVIE INC. | 35 | $442 |
| Janssen Pharmaceuticals, Inc | 20 | $390 |
| E.R. Squibb & Sons, L.L.C. | 32 | $354 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $306 |
| Otsuka America Pharmaceutical, Inc. | 20 | $294 |
| Neurocrine BioSciences, Inc. | 15 | $235 |
| Bausch Health US, LLC | 6 | $104 |
| Lundbeck LLC | 4 | $72 |
Products named: VRAYLAR, UZEDY, LYBALVI, COBENFY, ARISTADA, CAPLYTA, INGREZZA, SPRAVATO.
Industry payments across NJ — which companies pay providers there.
